Tirzepatid · DOSSIER

Tirzepatid

Tirzepatide · Mounjaro · Peptide · 39 AS
LEGAL DE · PRESCRIPTION-ONLYEVIDENCE · CLINICALLY ESTABLISHED3 STUDIES
SUMMARY

In a large trial, participants lost about 20 % of their body weight on average.

FIG.01 — SIGNAL CHAIN
EVIDENCE LEVELSPROVEN IN HUMANSANIMAL MODELS ONLYMECHANISM ONLYUNPROVEN IN HUMANS
01

What it does in the body

Findings, each with its evidence level — animal data kept visibly apart from what's unproven in humans.

Strong weight loss

In a large trial, participants lost about 20 % of their body weight on average.

PROVEN IN HUMANS
Lowers blood sugar

Acts on two gut-hormone signals at once to boost insulin release — proven in type-2 diabetes.

PROVEN IN HUMANS
Outperformed pure GLP-1

In a head-to-head trial it lowered blood sugar and weight more than semaglutide.

PROVEN IN HUMANS
Acts on adipose tissue

Also acts directly on fat tissue (as described in research).

MECHANISM ONLY
02

Mechanism of action

What Tirzepatid does in the body — step by step.

01

Tirzepatide is a dual agonist at GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors.

02

It is a synthetic 39-amino-acid peptide with a C20 fatty-acid side chain that enables binding to albumin and thus a half-life of about 5 days.

03

The simultaneous activation of both incretin receptors is intended to produce synergistic effects on insulin secretion, glucagon inhibition and food intake compared with pure GLP-1 agonists.

03

Research status

How far along is the evidence?

PRECLINICALEARLY CLINICAL STUDIESCLINICALLY ESTABLISHED
The SURPASS study programme (5 Phase III studies) comprehensively investigated tirzepatide in type 2 diabetes.
The SURPASS study programme (5 Phase III studies) comprehensively investigated tirzepatide in type 2 diabetes.
SURPASS-2 (2021) compared tirzepatide with semaglutide in a head-to-head design and observed numerically greater HbA1c reductions and weight loss with tirzepatide.
The SURMOUNT programme addressed obesity without diabetes: SURMOUNT-1 (2022) documented average weight reductions of about 20% versus baseline.
SURPASS-CVOT (2024) investigated cardiovascular endpoints.
Current research relates to heart failure (SUMMIT study) and sleep apnoea (SURMOUNT-OSA).
04

Known risks

Without human data, safety statements are limited. What is known:

01
Gastrointestinal side effects: nausea, vomiting, diarrhoea, constipation (the most common side effects in studies)
02
Hypoglycaemia risk in combination with insulin or sulfonylureas
03
Pancreatitis: rare isolated cases described; caution with a prior history
04
Thyroid C-cell tumours in animal models; clinical relevance in humans unclear
05
Gallbladder disease (cholelithiasis) possible with rapid weight loss
06
Heart rate increase of about 2–4 bpm observed in studies
07
Contraindication: personal or family history of medullary thyroid carcinoma or MEN2
05

Cited studies

Chronological — links lead to the source.

2021
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)
PubMed 34170647 →
2022
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
PubMed 35951447 →
2024
Tirzepatide and Cardiovascular Outcomes in Obesity with Heart Failure (SUMMIT)
PubMed 39466076 →
06

Frequently asked questions

What is Tirzepatid?+

Tirzepatide is a dual agonist at GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors.

What type of peptide is Tirzepatid?+

Tirzepatid belongs to the GLP-1 analog class.

What is Tirzepatid used for?+

In research, Tirzepatid has primarily been investigated in the context of: Metabolism. These are research findings (evidence: clinically established), not proven benefits in humans and not a usage recommendation.

Is Tirzepatid legal in Germany?+

Tirzepatid is prescription-only in Germany and may only be obtained with a medical prescription.

Is Tirzepatid FDA-approved / legal in the US?+

Tirzepatid is a prescription, FDA-approved medication in the US.

Is Tirzepatid legal in Canada?+

Tirzepatid is a prescription medication authorized by Health Canada.

Where can I buy Tirzepatid?+

Peptica sells nothing and names no sources. Tirzepatid is "prescription-only" in Germany; obtaining unapproved substances outside clinical studies is illegal and carries quality and safety risks.

What is the dosage of Tirzepatid?+

Peptica publishes no dosing. Tirzepatid is a prescription medicine — any dosing is determined individually by a physician. This is not medical advice.

Is Tirzepatid banned in sport (WADA)?+

Tirzepatid is currently not on the WADA Prohibited List.

What are the known risks of Tirzepatid?+

Documented risks include: Gastrointestinal side effects: nausea, vomiting, diarrhoea, constipation (the most common side effects in studies); Hypoglycaemia risk in combination with insulin or sulfonylureas. This is not a complete safety assessment and not medical advice — see the risks section for the full list.

How well researched is Tirzepatid?+

The evidence is classified as “clinically established”. 3 studies are cited on this page.

What is the molecular weight of Tirzepatid?+

Tirzepatid has a molar mass of about 4813.45 Da, with a plasma half-life of ~5 days.

Which peptides are related to Tirzepatid?+

Closely related entries: Retatrutid, Semaglutid. A direct side-by-side comparison is available via the compare function.

07

Dossier

Legal · Structure · Sources.

LEGAL STATUS BY REGION
Germanyprescription-only

Tirzepatide is approved in the EU as Mounjaro — for type 2 diabetes (2022) and for obesity (2024). In the USA it is additionally approved as Zepbound for obesity. Obtaining it without a medical prescription is illegal in Germany under § 48 AMG. Not on the WADA Prohibited List; monitoring status currently not specified.

Legal status varies by country and can change. This is not legal advice.

SOURCES & EXTERNAL DATABASES

Methodology: Peptica compiles publicly available studies and regulatory information and assigns each statement an evidence level. Not medical advice. No warranty.

RELATED PEPTIDES & FURTHER READING
08

Community notes

Note: These posts are user opinions and not medical advice. Posts containing dosages, therapeutic claims or purchase recommendations are removed. All entries are manually reviewed before publication.
This page is intended solely for factual, scientifically oriented information. No medical advice · no dosage or usage recommendations · no claims of efficacy · no substitute for medical consultation. Peptica sells no substances. Partner links are marked as advertising; Peptica may earn a commission. © 2026 Peptica · Issue 01